Delivery Order SPE2DB25D3002-SPE2DB26FLPKA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $11,411.43 under a firm fixed-price contract. The delivery order is non-set-aside and carries an ultimate completion date of September 4, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $16,453.58. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and no set-aside designation was used in the award. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order contract to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This non-competitive, firm fixed-price delivery order carries a ceiling value of $15,381.06 with an ultimate completion date of September 8, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes on July 14, 2025, with a contract ceiling value of $3,662.95. This order is not set-aside and was competitively awarded under a firm fixed-price arrangement, with an ultimate completion date of July 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This is a non-set-aside, competitively awarded contract with a firm fixed price ceiling value of $9,793.69 and a completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Actemra 162 mg/0.9 mL syringes, with a ceiling value of $23,369.56 and a firm fixed price structure. The delivery order is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. Performance is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of ACTEMRA 162 mg/0.9 mL syringes with a ceiling value of $4,687.56. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive procurement practices. The order is scheduled for ultimate completion by September 9, 2025, with fulfillment to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $19,792.71 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed price, competitively awarded contract was executed on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with...
- SPE2DB25D3002Indefinite Delivery Contract
- SPE2DB25D3002-SPE2DB26FLPKADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $8,326.33 under a firm fixed-price contract. This delivery order is non-set-aside and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of November 4, 2025. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. As a prime contractor under the DLA Troop Support Medical Indefinite Delivery Contract, the company supplies a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies to support military healthcare programs worldwide. This delivery order for Actemra, a biologic immunosuppressant used in rheumatologic treatment, exemplifies the company's role in fulfilling critical pharmaceutical requirements for the Defense Health Agency and other federal healthcare systems through competitive procurement mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 11/3/25 |